Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
Journal
-
- Annals of Oncology
-
Annals of Oncology 26 (9), 1877-1883, 2015-09
Elsevier BV
- Tweet
Details 詳細情報について
-
- CRID
- 1360855571460671744
-
- ISSN
- 09237534
-
- Data Source
-
- Crossref